A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan

We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.

Authors

Institutions

Publication Details

Journal
Congenital Anomalies
Published
2024-12-01
DOI
https://doi.org/10.1111/cga.12588
Citations
3
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan

Taku Obara, Atsuko Murashima, Akira Toyama, Naoto Suzuki et al.
3 citations
Congenital Anomalies
Pregnancy and Medication Impact
1.63
article

A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan

Taku Obara, Atsuko Murashima, Akira Toyama, Naoto Suzuki, Ritsuko Yamane, Mikako Goto, Takeo Nakayama, Masahiro Hayashi, Ken Nakajima, Yoshiyuki Saito, Kunihiko Takahashi, M. Honma
article en
3 citations

Abstract

We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.

Congenital AnomaliesVol. 65(1)
Tokyo Medical and Dental University (JP), Tohoku University (JP), Kyoto University (JP), Yokohama Minami Kyosai Hospital (JP), Tohoku University Hospital (JP), Niigata University Medical and Dental Hospital (JP), National Center For Child Health and Development (JP), Tohoku Medical Megabank Organization (JP), Toranomon Hospital (JP)
Good health and well-being
Openalex Percentile: Top 15%
Pregnancy and Medication Impact
1.63
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.